First-Line Drug Therapy for Psoriasis in a Hypertensive Patient

QUESTION

NR 500 NP WEEK 4 DiscussP. B. is a 58-year-old woman with a history of hypertension. She seeks treatment for scattered plaques with a silvery-white scale on her elbows, forearms, and knees. The body surface area affected is approximately 8%. She is very self-conscious about the lesions: “I just want them to go away.” Her medications include propranolol 40 mg thrice daily and furosemide 40 mg daily. She has a positive family history of psoriasis and reports high levels of stress in her job and life. She smokes a pack of cigarettes per day. Diagnosis: Psoriasis What drug therapy would you prescribe first line?

ANSWER

First-Line Drug Therapy for Psoriasis in a Hypertensive Patient

Introduction

Psoriasis is a chronic, immune-mediated skin disorder characterized by the presence of plaques with silvery-white scales. The treatment of psoriasis often involves a combination of therapies, tailored to the patient’s specific condition and considerations. In the case of P. B., a 58-year-old woman with a history of hypertension, it is crucial to select a first-line drug therapy that addresses her psoriasis effectively while considering her underlying medical conditions and lifestyle factors.

First-Line Drug Therapy

Given P. B.’s history of hypertension, it is important to choose a first-line drug therapy for psoriasis that is not contraindicated and is suitable for a patient with hypertension. In this case, topical treatments are typically preferred as a first-line option, especially for localized psoriasis involving less than 10% of the body surface area, as is the case with P. B.’s 8% involvement.

Topical Corticosteroids: Topical corticosteroids are the first-line choice for psoriasis patients with localized and mild to moderate involvement. These medications are available in various strengths and formulations, making them suitable for the affected areas on the elbows, forearms, and knees. They work by reducing inflammation and suppressing the immune response in the skin.

P. B. can be started on a low-to-moderate potency topical corticosteroid, which is less likely to exacerbate her hypertension.
Proper application instructions, including sparing use and avoidance of occlusion, should be provided.
Regular monitoring for side effects, such as skin thinning, should be ensured.

Lifestyle Modifications: Alongside topical treatment, P. B. should be strongly encouraged to make essential lifestyle changes that can significantly impact her psoriasis. These include:

Smoking Cessation: Given her one-pack-per-day smoking habit, quitting smoking is of utmost importance. Smoking can exacerbate psoriasis and limit the effectiveness of treatments.
Stress Management: Stress is a known trigger for psoriasis flare-ups. P. B. should be provided with stress management techniques or referred to a mental health professional to address her high-stress levels.

Education and Follow-Up: P. B. should receive comprehensive education on psoriasis, its management, and the importance of adherence to the prescribed treatment plan. Regular follow-up appointments should be scheduled to assess treatment response, monitor blood pressure, and make any necessary adjustments to the treatment regimen.

Cardiovascular Assessment: Given her hypertension and antihypertensive medication (propranolol), regular monitoring of her cardiovascular status is essential. Her antihypertensive therapy should be reviewed to ensure it does not worsen her psoriasis.

Conclusion

For a patient like P. B. with localized psoriasis and a history of hypertension, a first-line approach involving low-to-moderate potency topical corticosteroids is the most appropriate initial treatment. This choice addresses her skin condition effectively while considering her underlying medical conditions. Simultaneously, P. B. should be supported in adopting a healthier lifestyle by quitting smoking and managing stress, with regular follow-up appointments to monitor her progress and modify treatment as needed.